Post-surgery targeted therapy for remaining lung nodules in EGFR-mutant NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple early lung spots on both sides, and one side has been surgically removed
- The removed lung cancer tested positive for an EGFR gene mutation (either exon 19 deletion or exon 21 L858R)
- After surgery, you still have at least one suspicious spot in the other lung that is at least 8mm (or 1cm if it's a pure ground-glass nodule) but less than 3cm
- You are in good general health (able to do daily activities) and have no severe heart, lung, liver, or kidney problems
- You have not had other cancers in the last 5 years (except very curable ones like some skin or early breast cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests whether removing the main lung tumor with surgery, combined with an EGFR-targeted pill, can help people with stage IV lung cancer that has a specific EGFR mutation. The goal is to improve outcomes compared with medication alone.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.